Literature DB >> 16004166

Clinical description and follow-up investigation of human West Nile virus cases.

Kristy Gottfried1, Robbie Quinn, Tim Jones.   

Abstract

OBJECTIVES: The objective of this study was to investigate long-term outcomes after West Nile virus infection.
METHODS: We reviewed the medical records of persons reported with West Nile virus in Tennessee in 2002 and interviewed cases 1 year after acute illness.
RESULTS: In 2002, 56 cases of West Nile virus were reported in Tennessee; 48 (84%) had meningitis or encephalitis. Of those, 9 (19%) died during acute infection and 12 (25%) died within 6 months of illness onset. Patients with West Nile virus neurologic illness spent a median of 10 days in the hospital and were unable to resume normal activities for a median of 25 days. One year later, 12 of 22 (55%) persons reported that they were not fully recovered, with symptoms including fatigue, weakness, difficulty ambulating, and memory problems.
CONCLUSIONS: West Nile virus infection leads to high rates of mortality and substantial persistent morbidity. Prevention efforts should be targeted to populations at highest risk of severe sequelae.

Entities:  

Mesh:

Year:  2005        PMID: 16004166     DOI: 10.1097/01.SMJ.0000155633.43244.AC

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  12 in total

1.  Demographic and clinical factors associated with persistent symptoms after West Nile virus infection.

Authors:  Robert L Cook; Xiaohui Xu; Eric J Yablonsky; Nikole Sakata; Jennifer H Tripp; Rachel Hess; Paolo Piazza; Charles R Rinaldo
Journal:  Am J Trop Med Hyg       Date:  2010-11       Impact factor: 2.345

Review 2.  Neurological approaches for investigating West Nile virus disease and its treatment in rodents.

Authors:  John D Morrey; Venkatraman Siddharthan; Hong Wang
Journal:  Antiviral Res       Date:  2013-09-19       Impact factor: 5.970

3.  Treatment of spatial memory impairment in hamsters infected with West Nile virus using a humanized monoclonal antibody MGAWN1.

Authors:  Cynthia A Smeraski; Venkatraman Siddharthan; John D Morrey
Journal:  Antiviral Res       Date:  2011-04-30       Impact factor: 5.970

4.  A Mouse Model of West Nile Virus Infection.

Authors:  Jessica B Graham; Jessica L Swarts; Jennifer M Lund
Journal:  Curr Protoc Mouse Biol       Date:  2017-12-20

5.  Persistence of West Nile virus in the central nervous system and periphery of mice.

Authors:  Kim K Appler; Ashley N Brown; Barbara S Stewart; Melissa J Behr; Valerie L Demarest; Susan J Wong; Kristen A Bernard
Journal:  PLoS One       Date:  2010-05-14       Impact factor: 3.240

6.  Genetic diversity in the collaborative cross model recapitulates human West Nile virus disease outcomes.

Authors:  Jessica B Graham; Sunil Thomas; Jessica Swarts; Aimee A McMillan; Martin T Ferris; Mehul S Suthar; Piper M Treuting; Renee Ireton; Michael Gale; Jennifer M Lund
Journal:  MBio       Date:  2015-05-05       Impact factor: 7.867

7.  Neuropsychological Impact of West Nile Virus Infection: An Extensive Neuropsychiatric Assessment of 49 Cases in Canada.

Authors:  Zainab Samaan; Stephanie McDermid Vaz; Monica Bawor; Tammy Hlywka Potter; Sasha Eskandarian; Mark Loeb
Journal:  PLoS One       Date:  2016-06-28       Impact factor: 3.240

8.  Morbidity, mortality and long-term sequelae of West Nile virus disease in Québec.

Authors:  N Ouhoumanne; A-M Lowe; A Fortin; D Kairy; A Vibien; J K-Lensch; T-N Tannenbaum; F Milord
Journal:  Epidemiol Infect       Date:  2018-03-28       Impact factor: 4.434

9.  Survival analysis, long-term outcomes, and percentage of recovery up to 8 years post-infection among the Houston West Nile virus cohort.

Authors:  Kristy O Murray; Melissa N Garcia; Mohammad H Rahbar; Diana Martinez; Salma A Khuwaja; Raouf R Arafat; Susan Rossmann
Journal:  PLoS One       Date:  2014-07-23       Impact factor: 3.240

Review 10.  Neurological Sequelae Resulting from Encephalitic Alphavirus Infection.

Authors:  Shannon E Ronca; Kelly T Dineley; Slobodan Paessler
Journal:  Front Microbiol       Date:  2016-06-20       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.